Navigation Links
Regulation of cell proliferation by the OGF-OGFr axis is dependent on nuclear localization signals
Date:4/22/2009

GF-OGFr complex involves the shuttling of the peptide-receptor complex from the cytoplasm to the nucleus, as well as transport receptors.

The research team was comprised of Dr. Ian S. Zagon, Distinguished University Professor, and Dr. Patricia J. McLaughlin, Professor, along with a postdoctoral fellow Dr. Fan Cheng, in the Department of Neural & Behavioral Sciences. Drs. Zagon and McLaughlin discovered the growth related activity of endogenous opioids, identified OGF as the specific peptide, cloned and sequenced OGFr, and collaborated on demonstrating the remarkable properties of these native peptides in a variety of clinical studies. OGF has proven successful in a Phase I clinical, trial, and Phase II trials for pancreatic cancer and squamous cell carcinoma of the head and neck are in progress. Co-author Dr. McLaughlin states: "Given the extraordinary biological control of the cell cycle by the OGF-OGFr axis, it may be envisioned that either a loss or a gain in transport shuttling pathways could contribute to the onset and progression of disease." Dr. Zagon adds that "The clinical implications of the study speak to whether changes in nucleocytoplasmic machinery related to the OGF-OGFr axis, part of the body's own machinery governing physiological processes, may be involved with understanding the etiology and pathogenesis of human disease, as well as the basis for the treatment of human disorders."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said "Zagon and colleagues have discovered that the Opioid Growth Factor (OGF, [Met5]-enkephalin), a clinically important antitumor agent, is dependent on shuttling of the peptide and the OGF receptor from the cytoplasm to the nucleus. This discovery may provide valuable information to understanding the etiology and pathogenesis of diseases related to this native biological system, as well as to development of new agents that will enhance treatment effectiveness". <
'/>"/>

Contact: Dr. Ian S. Zagon
isz1@psu.edu
717-531-6409
Society for Experimental Biology and Medicine
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related biology news :

1. A paradigm shift in immune response regulation
2. Unclear regulations obstacle to biological diversity
3. New edition of laboratory manual includes cutting-edge techniques to study gene regulation
4. Scientists shed light on evolution of gene regulation
5. Conaway Lab identifies novel mechanism for regulation of gene expression
6. CU-Boulder study suggests air quality regulations miss key pollutants
7. Carbon Disclosure Project: Worlds largest corporations seek clarity on climate change regulation
8. New insights into the regulation of PTEN tumor suppression function
9. New regulations tighten controls on restricted chemicals
10. Systems biology approach identifies nutrient regulation of biological clock in plants
11. Epigenetic regulation by the MMB/dREAM complex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to dege
(Date:12/3/2009)PHILADELPHIA Now in its 32nd year, the CTRC-AACR San Antonio Breast Cancer Symposium continues to attract the best in breast cancer science and world leaders from industry and academia with the goal
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
Breaking Biology News(10 mins):Papillomavirus silences innate immune response 2CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 1HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 2HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 3CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 1CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 2CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 3CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 4Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 1Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 2Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 3Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 4
...ester scientists are to investigate the biological... after Alzheimer,s, thanks to a prestigious 1.9 mi...earch Council. , Frontotemporal lobar degeneratio...rontal and temporal lobes of the brain and are cha...rather than the memory loss associated with Alzhei...
...utions to Identify Individuals for Access to ...ions, WALL, N.J., Sept. 22 BIO-key International...er-based biometric,identification and wireless pub...etwork, is showcasing its fingerprint biometric so... being held at the Moscone Center in San,Francisco...
...A glitch in the ability to move iron around in cel...idosis (ML4) and the suite of symptoms---mental re...ies---that accompany it, new research at the Unive... may be involved in aging and neurodegenerative di...ead author Haoxing Xu, an assistant professor of m...
Other Biology News:£2 million study to reveal workings of dementia genes 2BIO-key(R) International To Exhibit at Oracle OpenWorld 2BIO-key(R) International To Exhibit at Oracle OpenWorld 3BIO-key(R) International To Exhibit at Oracle OpenWorld 4Iron-moving malfunction may underlie neurodegenerative diseases, aging 2Iron-moving malfunction may underlie neurodegenerative diseases, aging 3
(Date:12/2/2009)MANILA, Philippines, Dec. 2 Spectrum Blue Steel is emerging as one of the fastest growing green energy companies on the planet. Through the efforts of True Green Energy Group and True Green Planet,s
(Date:12/2/2009)NEW YORK, Dec. 2 Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugur
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...France, April 23 , - Strong 10.3% Growth in F...the world leader in ophthalmic optics, today,annou...the three months ended,March 31, 2009, representin...f 2008. Excluding the currency effect, growth was ...and early in the year, revenue was down just 1%,li...
...l 22 Hovione held today the opening,ceremony of i...ing site in,Cork. Hovione contracted with Pfizer l...anufacturing Lipitor(R) since 1997. The handover o...ction closed on the 8th; going forward,Hovione wil...e for Pfizer but,will mostly make use of the avail...
...inducted into National Academy of Sciences for gro... WASHINGTON, April 22 Sir Philip Cohen of Scotlan...he U.S. National Academy of Sciences (NAS) during ...8:00 p.m. at the NAS building for his excellence i...of only four Scottish scientists ever inducted int...
Other Biology Technology:Essilor : 2009 First Quarter Report 2Essilor : 2009 First Quarter Report 3Essilor : 2009 First Quarter Report 4Hovione Opens its New API Plant in Cork 2Hovione Opens its New API Plant in Cork 3United States Recognizes Leading Scottish Scientist for Disease Research 2
... containing a clone of the human Topoisomerase II ... topological state of nucleic acids by passing an ...enerates a separate DNA helix (1,2) . As a result ...enzyme can relax negatively or positively supercoi...
...I catalyzes the template-directed polymerization o...DNA Polymerase I possesses a 3?5 exonuclease activ...rror rate during DNA replication, and also contain...zyme to replace nucleotides in the growing strand ...
...e Klenow Fragment is a genetically engineered Klen...vity has been removed, leaving only the 5 to 3 pol...ctivity makes Exo- Klenow Fragment the enzyme of c...s by the random primed method, and for DNA sequenc...
T7 RNA Polymerase from Invitrogen
Biology Products: